Close
x
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c

Home > Markets > IPO > IPO News
Select Items

IPO News

31-Jul-2021 (15:11) Rolex Rings IPO ends with robust subscriptions

The initial public offer of automotive component maker Rolex Rings received bids for 74.15 crore shares as against 56.85 lakh shares on offer. The issue was subscribed 130.43 times.

The non-institutional investors (NIIs) category was subscribed 360.11 times. The qualified institutional buyers (QIBs) category was subscribed 143.58 times. The retail individual investors (RIIs) category was subscribed 24.48 times.

The issue opened for bidding on Wednesday (28 July 2021) and closed on Friday (30 July 2021). The price band of the IPO was fixed at Rs 880-900 per share.

The IPO comprised of fresh issue of equity shares aggregating upto Rs 56 crore and an offer for sale (OFS) of 75 lakh equity shares by Rivendell PE LLC, the investor shareholder. Post issue the selling shareholder will have a holding of 34,14,423 equity share amounting about 21.75% of the post issue share capital.

While the company will not get any proceeds from the OFS, about Rs 45 crore out of the proceeds from fresh issue will be used for funding long-term working capital requirements and balance for general corporate purposes.

Ahead of the IPO, Rolex Rings on 27 July 2021 finalized allocation of 24,36,666 equity shares to anchor investors, at Rs 900 per equity share, aggregating to Rs 219.29 crore.

Rolex Rings is one of the leading forging companies in the country engaged in manufacture and supply of hot rolled forged and machined bearing rings and automotive components. The company supplies domestically and internationally to large marquee customers including some of the leading bearing manufacturing companies, tier-I suppliers to global auto companies and some auto OEMs. It is one of the key manufacturers of bearing rings in India and cater to most of the leading bearing companies in India. In FY2021, about 58.2% of its revenue come from bearing rings and balance 41.8% from auto-components.

The company reported a net profit of Rs 86.96 crore and sales of Rs 616.33 crore in the twelve months ended 31 March 2021.

Powered by Capital Market - Live News

30-Jul-2021 (17:16) Rolex Rings IPO subscribed 130.43 times

The initial public offer of automotive component maker Rolex Rings received bids for 74.15 crore shares as against 56.85 lakh shares on offer on Friday (30 July 2021), according to stock exchange data at 17:00 IST. The issue was subscribed 130.43 times.

The issue opened for bidding on Wednesday (28 July 2021) and it will close today (30 July 2021). The price band of the IPO was fixed at Rs 880-900 per share.

The IPO comprised of fresh issue of equity shares aggregating upto Rs 56 crore and an offer for sale (OFS) of 75 lakh equity shares by Rivendell PE LLC, the investor shareholder. Post issue the selling shareholder will have a holding of 34,14,423 equity share amounting about 21.75% of the post issue share capital.

While the company will not get any proceeds from the OFS, about Rs 45 crore out of the proceeds from fresh issue will be used for funding long-term working capital requirements and balance for general corporate purposes.

Ahead of the IPO, Rolex Rings on 27 July 2021 finalized allocation of 24,36,666 equity shares to anchor investors, at Rs 900 per equity share, aggregating to Rs 219.29 crore.

Rolex Rings is one of the leading forging companies in the country engaged in manufacture and supply of hot rolled forged and machined bearing rings and automotive components. The company supplies domestically and internationally to large marquee customers including some of the leading bearing manufacturing companies, tier-I suppliers to global auto companies and some auto OEMs. It is one of the key manufacturers of bearing rings in India and cater to most of the leading bearing companies in India. In FY2021, about 58.2% of its revenue come from bearing rings and balance 41.8% from auto-components.

The company reported a net profit of Rs 86.96 crore and sales of Rs 616.33 crore in the twelve months ended 31 March 2021.

Powered by Capital Market - Live News

30-Jul-2021 (17:04) Glenmark Life Sciences IPO ends with robust subcription

The initial public offer of bulk drug and contract manufacturer Glenmark Life Sciences received bids for 66.33 crore shares as against 1.50 crore shares on offer, according to stock exchange data. The issue was subscribed 44.17 times.

The issue opened for bidding on Tuesday (27 July 2021) and closed on Thursday (29 July 2021). The price band of the IPO was fixed at Rs 695-720 per share.

The IPO comprised of fresh issue of equity shares worth up to Rs 1,060 crore and an offer for sale of up to 63 lakh equity shares by existing shareholder Glenmark Pharmaceuticals.

Glenmark Pharmaceuticals is the promoter of the company, which currently holds an aggregate of 10,78,04,950 equity shares, aggregating to 100% of the pre-offer issued and paid-up equity share capital. The post IPO shareholding for the same is expected to be around 82.84%.

The proceeds from the issue will be used for payment of Rs 800 crore of outstanding purchase consideration to the Promoter Glenmark Pharmaceutical for the spin-off of the API business through business purchase agreement, funding the capital expenditure requirements of Rs 152.7 crore and remaining amount will be used for general corporate purposes.

Ahead of the IPO, Glenmark Life Sciences on 26 July 2021 allotted 63,06,660 equity shares to 19 anchor investors, at Rs 720 per equity share, aggregating to Rs 454.07 crore.

Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. The company also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas.

The API portfolio of the company comprises of specialized and profitable products which includes niche and technically complex molecules. The company has the capacity to branch into other high value products. As of 31 December 2020, the company had a portfolio of 120 molecules globally.

Glenmark Life Sciences reported a net profit of Rs 351.58 crore and sales of Rs 1,885.17 crore in the twelve months ended 31 March 2021.

Powered by Capital Market - Live News

29-Jul-2021 (18:07) Rolex Rings IPO subscribed 9.26 times

The initial public offer of automotive component maker Rolex Rings received bids for 5.26 crore shares as against 56.85 lakh shares on offer on Thursday (29 July 2021), according to stock exchange data at 17:00 IST. The issue was subscribed 9.26 times.

The issue opened for bidding on Wednesday (28 July 2021) and it will close Friday (30 July 2021). The price band of the IPO was fixed at Rs 880-900 per share. An investor can bid for a minimum of 16 equity shares and in multiples thereof.

The IPO comprises of fresh issue of equity shares aggregating upto Rs 56 crore and an offer for sale (OFS) of 75 lakh equity shares by Rivendell PE LLC, the investor shareholder. Post issue the selling shareholder will have a holding of 34,14,423 equity share amounting about 21.75% of the post issue share capital.

While the company will not get any proceeds from the OFS, about Rs 45 crore out of the proceeds from fresh issue will be used for funding long-term working capital requirements and balance for general corporate purposes.

Ahead of the IPO, Rolex Rings on 27 July 2021 finalized allocation of 24,36,666 equity shares to anchor investors, at Rs 900 per equity share, aggregating to Rs 219.29 crore.

Rolex Rings is one of the leading forging companies in the country engaged in manufacture and supply of hot rolled forged and machined bearing rings and automotive components. The company supplies domestically and internationally to large marquee customers including some of the leading bearing manufacturing companies, tier-I suppliers to global auto companies and some auto OEMs. It is one of the key manufacturers of bearing rings in India and cater to most of the leading bearing companies in India. In FY2021, about 58.2% of its revenue come from bearing rings and balance 41.8% from auto-components.

The company reported a net profit of Rs 86.96 crore and sales of Rs 616.33 crore in the twelve months ended 31 March 2021.

Powered by Capital Market - Live News

29-Jul-2021 (18:03) Glenmark Life Sciences IPO subscribed 44.17 times

The initial public offer of bulk drug and contract manufacturer Glenmark Life Sciences received bids for 66.33 crore shares as against 1.50 crore shares on offer on Thursday (29 July 2021), according to stock exchange data at 17:00 IST. The issue was subscribed 44.17 times.

The issue opened for bidding on Tuesday (27 July 2021) and it will close today (29 July 2021). The price band of the IPO was fixed at Rs 695-720 per share.

The IPO comprised of fresh issue of equity shares worth up to Rs 1,060 crore and an offer for sale of up to 63 lakh equity shares by existing shareholder Glenmark Pharmaceuticals.

Glenmark Pharmaceuticals is the promoter of the company, which currently holds an aggregate of 10,78,04,950 equity shares, aggregating to 100% of the pre-offer issued and paid-up equity share capital. The post IPO shareholding for the same is expected to be around 82.84%.

The proceeds from the issue will be used for payment of Rs 800 crore of outstanding purchase consideration to the Promoter Glenmark Pharmaceutical for the spin-off of the API business through business purchase agreement, funding the capital expenditure requirements of Rs 152.7 crore and remaining amount will be used for general corporate purposes.

Ahead of the IPO, Glenmark Life Sciences on 26 July 2021 allotted 63,06,660 equity shares to 19 anchor investors, at Rs 720 per equity share, aggregating to Rs 454.07 crore.

Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. The company also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas.

The API portfolio of the company comprises of specialized and profitable products which includes niche and technically complex molecules. The company has the capacity to branch into other high value products. As of 31 December 2020, the company had a portfolio of 120 molecules globally.

Glenmark Life Sciences reported a net profit of Rs 351.58 crore and sales of Rs 1,885.17 crore in the twelve months ended 31 March 2021.

Powered by Capital Market - Live News

28-Jul-2021 (17:58) Rolex Rings IPO subscribed 3.84 times

The initial public offer of automotive component maker Rolex Rings received bids for 2.18 crore shares as against 56.85 lakh shares on offer on Wednesday (28 July 2021), according to stock exchange data at 17:00 IST. The issue was subscribed 3.84 times.

The issue opened for bidding on Wednesday (28 July 2021) and it will close Friday (30 July 2021). The price band of the IPO was fixed at Rs 880-900 per share. An investor can bid for a minimum of 16 equity shares and in multiples thereof.

The IPO comprises of fresh issue of equity shares aggregating upto Rs 56 crore and an offer for sale (OFS) of 75 lakh equity shares by Rivendell PE LLC, the investor shareholder. Post issue the selling shareholder will have a holding of 34,14,423 equity share amounting about 21.75% of the post issue share capital.

While the company will not get any proceeds from the OFS, about Rs 45 crore out of the proceeds from fresh issue will be used for funding long-term working capital requirements and balance for general corporate purposes.

Ahead of the IPO, Rolex Rings on 27 July 2021 finalized allocation of 24,36,666 equity shares to anchor investors, at Rs 900 per equity share, aggregating to Rs 219.29 crore.

Rolex Rings is one of the leading forging companies in the country engaged in manufacture and supply of hot rolled forged and machined bearing rings and automotive components. The company supplies domestically and internationally to large marquee customers including some of the leading bearing manufacturing companies, tier-I suppliers to global auto companies and some auto OEMs. It is one of the key manufacturers of bearing rings in India and cater to most of the leading bearing companies in India. In FY2021, about 58.2% of its revenue come from bearing rings and balance 41.8% from auto-components.

The company reported a net profit of Rs 86.96 crore and sales of Rs 616.33 crore in the twelve months ended 31 March 2021.

Powered by Capital Market - Live News

28-Jul-2021 (17:50) Glenmark Life Sciences IPO subscribed 5.78 times

The initial public offer of bulk drug and contract manufacturer Glenmark Life Sciences received bids for 8.68 crore shares as against 1.50 crore shares on offer on Wednesday (28 July 2021), according to stock exchange data at 17:00 IST. The issue was subscribed 5.78 times.

The issue opened for bidding on Tuesday (27 July 2021) and it will close Thursday (29 July 2021). The price band of the IPO is fixed at Rs 695-720 per share. An investor can bid for a minimum of 20 equity shares and in multiples thereof.

The IPO comprises of fresh issue of equity shares worth up to Rs 1,060 crore and an offer for sale of up to 63 lakh equity shares by existing shareholder Glenmark Pharmaceuticals.

Glenmark Pharmaceuticals is the promoter of the company, which currently holds an aggregate of 10,78,04,950 equity shares, aggregating to 100% of the pre-offer issued and paid-up equity share capital. The post IPO shareholding for the same is expected to be around 82.84%.

The proceeds from the issue will be used for payment of Rs 800 crore of outstanding purchase consideration to the Promoter Glenmark Pharmaceutical for the spin-off of the API business through business purchase agreement, funding the capital expenditure requirements of Rs 152.7 crore and remaining amount will be used for general corporate purposes.

Ahead of the IPO, Glenmark Life Sciences on 26 July 2021 allotted 63,06,660 equity shares to 19 anchor investors, at Rs 720 per equity share, aggregating to Rs 454.07 crore.

Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. The company also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas.

The API portfolio of the company comprises of specialized and profitable products which includes niche and technically complex molecules. The company has the capacity to branch into other high value products. As of 31 December 2020, the company had a portfolio of 120 molecules globally.

Glenmark Life Sciences reported a net profit of Rs 351.58 crore and sales of Rs 1,885.17 crore in the twelve months ended 31 March 2021.

Powered by Capital Market - Live News

27-Jul-2021 (17:40) Glenmark Life Sciences IPO subscribed 2.78 times

The initial public offer of bulk drug and contract manufacturer Glenmark Life Sciences received bids for 4.17 crore shares as against 1.50 crore shares on offer on Tuesday (27 July 2021), according to stock exchange data at 17:00 IST. The issue was subscribed 2.78 times.

The issue opened for bidding on Tuesday (27 July 2021) and it will close Thursday (29 July 2021). The price band of the IPO is fixed at Rs 695-720 per share. An investor can bid for a minimum of 20 equity shares and in multiples thereof.

The IPO comprises of fresh issue of equity shares worth up to Rs 1,060 crore and an offer for sale of up to 63 lakh equity shares by existing shareholder Glenmark Pharmaceuticals.

Glenmark Pharmaceuticals is the promoter of the company, which currently holds an aggregate of 10,78,04,950 equity shares, aggregating to 100% of the pre-offer issued and paid-up equity share capital. The post IPO shareholding for the same is expected to be around 82.84%.

The proceeds from the issue will be used for payment of Rs 800 crore of outstanding purchase consideration to the Promoter Glenmark Pharmaceutical for the spin-off of the API business through business purchase agreement, funding the capital expenditure requirements of Rs 152.7 crore and remaining amount will be used for general corporate purposes.

Ahead of the IPO, Glenmark Life Sciences on 26 July 2021 allotted 63,06,660 equity shares to 19 anchor investors, at Rs 720 per equity share, aggregating to Rs 454.07 crore.

Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. The company also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas.

The API portfolio of the company comprises of specialized and profitable products which includes niche and technically complex molecules. The company has the capacity to branch into other high value products. As of 31 December 2020, the company had a portfolio of 120 molecules globally.

Glenmark Life Sciences reported a net profit of Rs 351.58 crore and sales of Rs 1,885.17 crore in the twelve months ended 31 March 2021.

Powered by Capital Market - Live News

21-Jul-2021 (09:14) Tatva Chintan Pharma Chem IPO ends with robust subscription

The initial public offer (IPO) of specialty chemicals manufacturing company Tatva Chintan Pharma Chem received bids for 58.83 crore shares as against 32.61 lakh shares on offer, according to stock exchange data. The issue was subscribed 180.36 times.

The non-institutional investors (NIIs) category was subscribed 512.22 times. The qualified institutional buyers (QIBs) category was subscribed 185.23 times. The retail individual investors (RIIs) category was subscribed 35.35 times.

The issue opened for bidding on Friday (16 July 2021) and closed on Tuesday (20 July 2021). The price band of the IPO was fixed at Rs 1073-1083 per share.

The offer comprised of a fresh issue of equity shares aggregating to Rs 225 crore by the company and an offer for sale by selling shareholders aggregating to Rs 275 crore.

Ahead of the IPO, Tatva Chintan Pharma Chem on 15 July 2021 allotted 13,85,040 equity shares to 22 anchor investors, at Rs 1,083 per equity share, aggregating to Rs 149.99 crore.

The proceeds from the offer for sale shall be received by the selling shareholders. The company proposes to utilize the net proceeds of the fresh issue towards funding capital expenditure requirements for expansion of its Dahej manufacturing facility amounting Rs 147.1 crore, funding capital expenditure requirements for upgradation at its R&D facility in Vadodara amounting Rs 23.971 crore and balance towards general corporate purposes.

The company reported a consolidated net profit of Rs 52.26 crore and total income of Rs 300.36 crore in the twelve months ended 31 March 2021.

Tatva Chintan Pharma Chem is a specialty chemicals manufacturing company engaged in the manufacturing of a diverse portfolio of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC).

It is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. In addition, the company is one of the leading global producers of anentire range of PTCs in India and one of the key producers across the globe. As on 31 March 2021, the company manufactures over 154 products.

Powered by Capital Market - Live News

20-Jul-2021 (17:32) Tatva Chintan Pharma Chem IPO subscribed 180.36 times

The initial public offer of specialty chemicals manufacturing company Tatva Chintan Pharma Chem received bids for 58.83 crore shares as against 32.61 lakh shares on offer on Tuesday (20 July 2021), according to stock exchange data at 17:00 IST. The issue was subscribed 180.36 times.

The issue opened for bidding on Friday (16 July 2021) and it will close today (20 July 2021). The price band of the IPO was fixed at Rs 1073-1083 per share.

The offer comprised of a fresh issue of equity shares aggregating to Rs 225 crore by the company and an offer for sale by selling shareholders aggregating to Rs 275 crore.

Ahead of the IPO, Tatva Chintan Pharma Chem on 15 July 2021 allotted 13,85,040 equity shares to 22 anchor investors, at Rs 1,083 per equity share, aggregating to Rs 149.99 crore.

The proceeds from the offer for sale shall be received by the selling shareholders. The company proposes to utilize the net proceeds of the fresh issue towards funding capital expenditure requirements for expansion of its Dahej manufacturing facility amounting Rs 147.1 crore, funding capital expenditure requirements for upgradation at its R&D facility in Vadodara amounting Rs 23.971 crore and balance towards general corporate purposes.

The company reported a consolidated net profit of Rs 52.26 crore and total income of Rs 300.36 crore in the twelve months ended 31 March 2021.

Tatva Chintan Pharma Chem is a specialty chemicals manufacturing company engaged in the manufacturing of a diverse portfolio of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC).

It is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. In addition, the company is one of the leading global producers of anentire range of PTCs in India and one of the key producers across the globe. As on 31 March 2021, the company manufactures over 154 products.

Powered by Capital Market - Live News

  • showing 1 to 10 of 100 entries
  • Show
  • entries
 PREVIOUS 123 NEXT